Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

More Patient Deaths Put Hold on Juno’s CAR-T Immunotherapy Clinical Trial

XTALKS VITALS NEWS

CAR-T

The Phase II clinical trial of Juno’s JCAR015 – named ROCKET – was voluntarily placed on hold following the adverse events.

Share this!

November 29, 2016 | by Sarah Hand, M.Sc.

Biopharmaceutical company Juno Therapeutics, has announced that more patients participating in their CAR-T immunotherapy clinical trial, have died as a result of the treatment. Two patients suffered severe cerebral edema – swelling of the brain – which led to the death of one patient, and the prediction that the other will not recover.

The Phase II clinical trial of Juno’s JCAR015 – named ROCKET – was voluntarily placed on hold following the adverse events. Just a few months ago, three patients with relapsed or refractory B cell acute lymphoblastic leukemia died during the course of the study, prompting the US Food and Drug Administration (FDA) to enforce a temporary clinical hold while the deaths were investigated.

Juno quickly identified a specific chemotherapy drug, fludarabine, as the cause of the patient deaths, which was used as a pre-conditioning treatment before the CAR-T cell therapy was administered. However, even after removing this drug from the study protocol after resuming the trial, the ROCKET trial has still been plagued by more patient deaths.

It is our view that the removal of fludarabine has reduced the incidence of severe neurotoxicity,” said Hans Bishop, CEO of Juno Therapeutics in a conference call regarding the trial last week. “It just hasn’t gotten us as far as we hoped that it would.”



Now that five patient deaths have been associated with the CAR-T immunotherapy trial, Juno is sure to face many questions regarding the safety of JCAR015. As the FDA was the one to allow the clinical trial to continue following the first deaths, the regulatory agency will likely face increased scrutiny over the coming weeks.

“It’s just terrible,” Brad Loncar, founder of a cancer immunotherapy fund, told Stat News. “They’ve killed a couple of people, and it seems like, in part, it’s because of the rush to judgment.”

According to Bishop, the patients participating in the ROCKET trial were already suffering the effects of the rare, but highly-lethal form of blood cancer before joining the study. As Juno still has other CAR-T clinical trials on the go, they could still meet their target of launching their first therapeutic by 2018.


Keywords: CAR-T, Immunotherapy, Clinical Trials


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.